D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 101 Citations 64,694 348 World Ranking 3653 National Ranking 106

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Surgery

The scientist’s investigation covers issues in Internal medicine, Oncology, Temozolomide, Surgery and Glioma. His Oncology research integrates issues from Clinical trial, Oligodendroglioma, Oligoastrocytoma and Erlotinib. His biological study spans a wide range of topics, including Pseudoprogression, Procarbazine and Performance status.

Martin J. van den Bent has researched Surgery in several fields, including Gastroenterology and Hazard ratio. His Glioma study combines topics from a wide range of disciplines, such as Biomarker, Personalized medicine, IDH1 and Pathology. Martin J. van den Bent studied Radiation therapy and Concomitant that intersect with Anaplastic astrocytoma.

His most cited work include:

  • Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma (12592 citations)
  • Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (4693 citations)
  • Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (2349 citations)

What are the main themes of his work throughout his whole career to date?

Martin J. van den Bent spends much of his time researching Internal medicine, Oncology, Glioma, Temozolomide and Radiation therapy. Martin J. van den Bent has included themes like Surgery and Oligodendroglioma in his Internal medicine study. His Surgery research is multidisciplinary, relying on both Gastroenterology and Hazard ratio.

His Oncology research focuses on Randomized controlled trial and how it connects with Physical therapy and Quality of life. He works mostly in the field of Glioma, limiting it down to concerns involving Pathology and, occasionally, Cancer. His Temozolomide research includes themes of Concomitant, Clinical endpoint, Adjuvant and Performance status.

He most often published in these fields:

  • Internal medicine (54.40%)
  • Oncology (46.76%)
  • Glioma (30.56%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (54.40%)
  • Oncology (46.76%)
  • Glioma (30.56%)

In recent papers he was focusing on the following fields of study:

Martin J. van den Bent mainly investigates Internal medicine, Oncology, Glioma, Clinical trial and Radiation therapy. His Internal medicine study which covers Gastroenterology that intersects with Asymptomatic. His Oncology research includes elements of Hazard ratio, Primary central nervous system lymphoma, Oligodendroglioma and Temozolomide.

His study looks at the relationship between Temozolomide and topics such as Lomustine, which overlap with Procarbazine. His work carried out in the field of Clinical trial brings together such families of science as Predictive value of tests, Quality of life, Intensive care medicine, Brain tumor and Magnetic resonance imaging. The Radiation therapy study combines topics in areas such as Interim analysis, O-6-methylguanine-DNA methyltransferase, Concomitant and Pharmacotherapy.

Between 2018 and 2021, his most popular works were:

  • Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study. (90 citations)
  • cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. (87 citations)
  • cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. (83 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Chemotherapy

Martin J. van den Bent mainly focuses on Internal medicine, Oncology, Clinical trial, Glioma and Intensive care medicine. His work deals with themes such as Glioblastoma, Temozolomide, Epidermal growth factor receptor and Hazard ratio, which intersect with Oncology. Martin J. van den Bent interconnects Bevacizumab, Adjuvant and Adverse effect in the investigation of issues within Temozolomide.

His Hazard ratio research is multidisciplinary, incorporating perspectives in Gross Total Resection and Resection. Martin J. van den Bent combines subjects such as Predictive value of tests, Patient advocacy, Brain tumor, Magnetic resonance imaging and Cooperative group with his study of Clinical trial. His studies in Glioma integrate themes in fields like Hippocampus and Radiation therapy.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Roger Stupp;Warren P. Mason;Martin J. van den Bent;Michael Weller.
The New England Journal of Medicine (2005)

16946 Citations

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp;Monika E. Hegi;Warren P. Mason;Martin J. van den Bent.
Lancet Oncology (2009)

7623 Citations

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Patrick Y. Wen;David R. Macdonald;David A. Reardon;Timothy F. Cloughesy.
Journal of Clinical Oncology (2010)

2941 Citations

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

Dieta Brandsma;Lukas Stalpers;Walter Taal;Peter Sminia.
Lancet Oncology (2008)

1223 Citations

Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma

Francesco Pignatti;Martin van den Bent;Desmond Curran;Channa Debruyne.
Journal of Clinical Oncology (2002)

1042 Citations

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

Martin J. van den Bent;Alba A. Brandes;Martin J.B. Taphoorn;Johan M. Kros.
Journal of Clinical Oncology (2013)

1016 Citations

Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

Martin J. van den Bent;Antoine F. Carpentier;Alba A. Brandes;Marc Sanson.
Journal of Clinical Oncology (2006)

946 Citations

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge.
Lancet Oncology (2014)

791 Citations

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

Walter Taal;Hendrika M Oosterkamp;Annemiek M E Walenkamp;Hendrikus J Dubbink.
Lancet Oncology (2014)

677 Citations

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

Michael Weller;Roger Stupp;Guido Reifenberger;Alba A. Brandes.
Nature Reviews Neurology (2010)

662 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Martin J. van den Bent

Michael Weller

Michael Weller

University of Zurich

Publications: 313

Wolfgang Wick

Wolfgang Wick

German Cancer Research Center

Publications: 300

Patrick Y. Wen

Patrick Y. Wen

Harvard University

Publications: 273

David A. Reardon

David A. Reardon

Harvard University

Publications: 203

Timothy F. Cloughesy

Timothy F. Cloughesy

University of California, Los Angeles

Publications: 200

Andreas von Deimling

Andreas von Deimling

Heidelberg University

Publications: 164

Mark R. Gilbert

Mark R. Gilbert

The University of Texas MD Anderson Cancer Center

Publications: 156

Tracy T. Batchelor

Tracy T. Batchelor

Brigham and Women's Hospital

Publications: 149

Jeremy N. Rich

Jeremy N. Rich

University of Pittsburgh

Publications: 139

Susan M. Chang

Susan M. Chang

University of California, San Francisco

Publications: 139

Roger Stupp

Roger Stupp

Northwestern University

Publications: 133

Kenneth D. Aldape

Kenneth D. Aldape

Princess Margaret Cancer Centre

Publications: 132

Tao Jiang

Tao Jiang

Capital Medical University

Publications: 123

Guido Reifenberger

Guido Reifenberger

Heinrich Heine University Düsseldorf

Publications: 120

Lisa M. DeAngelis

Lisa M. DeAngelis

Memorial Sloan Kettering Cancer Center

Publications: 119

Pieter Wesseling

Pieter Wesseling

University of Amsterdam

Publications: 117

Something went wrong. Please try again later.